onis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus (CHB). The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA for 24 weeks after end of bepirovirsen treatment in people with CHB. The study results were presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Washington, DC.
Reported Late Wednesday March 08, Bionomics Reports Promising Full Results Analysis From PREVAIL Phase 2 Study Of BNC210 Social Anxiety Disorder; PREVAIL Did Not Meet Its Primary Endpoint
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge
Results achieved statistical significance in post-hoc analysis of the full
